GUTS Fractyl Health Inc.
Price (delayed)
$1.16
Market cap
$56.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.62
Enterprise value
$51.78M
We are a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. Despite advances in treatment over the last
Highlights
The EPS has surged by 96% year-on-year and by 87% since the previous quarter
GUTS's gross margin is up by 29% year-on-year
Fractyl Health's equity has soared by 109% YoY but it has decreased by 44% from the previous quarter
GUTS's quick ratio is down by 37% since the previous quarter but it is up by 14% year-on-year
The revenue has declined by 23% year-on-year and by 4.1% since the previous quarter
GUTS's gross profit is down by 4.4% since the previous quarter
Key stats
What are the main financial stats of GUTS
Market
Valuations
Earnings
Shares outstanding
48.92M
Market cap
$56.75M
Enterprise value
$51.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.96
Price to sales (P/S)
543.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
556.81
Revenue
$93,000
Gross profit
$43,000
Operating income
-$93.53M
Net income
-$68.69M
EBIT
-$68.69M
EBITDA
-$66.15M
Free cash flow
-$67.29M
Per share
Balance sheet
Liquidity
EPS
-$1.62
EPS diluted
-$1.62
Free cash flow per share
-$1.55
Book value per share
$0.59
Revenue per share
$0
TBVPS
$2.48
Total assets
$108.08M
Total liabilities
$79.65M
Debt
$62.5M
Equity
$28.42M
Working capital
$51.99M
Debt to equity
2.2
Current ratio
3.63
Quick ratio
3.41
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
-71,126.9%
Gross margin
46.2%
Net margin
-73,864.5%
Operating margin
-100,571%
Return on assets
-51.7%
Return on equity
-120.6%
Return on invested capital
-78%
Return on capital employed
-77.8%
Return on sales
-73,864.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GUTS stock price
How has the Fractyl Health stock price performed over time
Intraday
4.5%
1 week
-8.66%
1 month
-25.64%
1 year
-82.79%
YTD
-43.69%
QTD
-2.52%
Financial performance
How have Fractyl Health's revenue and profit performed over time
Revenue
$93,000
Gross profit
$43,000
Operating income
-$93.53M
Net income
-$68.69M
Gross margin
46.2%
Net margin
-73,864.5%
The operating margin has dropped by 137% year-on-year and by 20% since the previous quarter
The company's operating income has shrunk by 84% YoY and by 15% QoQ
GUTS's gross margin is up by 29% year-on-year
The revenue has declined by 23% year-on-year and by 4.1% since the previous quarter
Growth
What is Fractyl Health's growth rate over time
Valuation
What is Fractyl Health stock price valuation
P/E
N/A
P/B
1.96
P/S
543.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
556.81
The EPS has surged by 96% year-on-year and by 87% since the previous quarter
Fractyl Health's equity has soared by 109% YoY but it has decreased by 44% from the previous quarter
GUTS's P/B is 41% below its last 4 quarters average of 3.2
The price to sales (P/S) is 62% lower than the last 4 quarters average of 1355.3
The revenue has declined by 23% year-on-year and by 4.1% since the previous quarter
Efficiency
How efficient is Fractyl Health business performance
The ROA has soared by 62% YoY and by 3.9% from the previous quarter
GUTS's return on invested capital is up by 28% year-on-year but it is down by 20% since the previous quarter
The return on sales has declined by 15% year-on-year and by 14% since the previous quarter
Dividends
What is GUTS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GUTS.
Financial health
How did Fractyl Health financials performed over time
Fractyl Health's total assets is 36% higher than its total liabilities
Fractyl Health's total assets has increased by 42% YoY but it has decreased by 15% QoQ
GUTS's quick ratio is down by 37% since the previous quarter but it is up by 14% year-on-year
GUTS's debt is 120% greater than its equity
Fractyl Health's equity has soared by 109% YoY but it has decreased by 44% from the previous quarter
Fractyl Health's debt to equity has surged by 76% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.